Shanghai Medicilon Inc.

  Amid the rapid advancement of AI, its application in drug development is gradually transforming the traditional pharmaceutical industry, driving drug research and development towards faster, stronger, and more precise innovation.  As a leader in the AI pharmaceutical field, Insilico Medicine has demonstrated impressive performance over the past few years. Whether in pipeline development, platform technology, or international collaborations, it has showcased its exceptional capabilities. Can AI-driven drug development ultimately lead to success in new drug research?  Can it effectively accelerate the drug development process through algorithms and data?  As a partner of Insilico Medicine, Medicilon is honored to invite Dr. Feng Ren, the joint CEO and Chief Scientific Officer of Insilico Medicine, to discuss and interpret the developments and trends of AI in new drug research and development. Dr. Feng Ren, joint CEO and Chief Scientific Officer of Insilico Medicine, ...

  Recently, ISM3412, a class 1 new drug developed by InSilico Medicine Cayman TopCo (Insilico Medicine), received implied approval for clinical trials in China. The indication is for advanced/metastatic solid tumors.  ISM3412 is a highly selective oral MAT2A inhibitor discovered with the assistance of artificial intelligence. It received FDA approval in April 2024 to conduct clinical trials in the United States for the treatment of MTAP- deficient cancers. As a strategic partner of Insilico Medicine, Medicilon provided preclinical research services for ISM3412, including  pharmacokinetics  and  safety evaluation tests . This support laid a solid foundation for the rapid approval of the drug. "Synthetic Lethality" New Target MAT2A      ISM3412 is expected to become "Best-in-Class" ISM3412 is a structurally novel and highly selective MAT2A inhibitor, designed with the assistance of Insilico Medicine's generative chemistry engine, Chemistry42, using ...